Antihistamines and Mast Cell Stabilizers in Allergic Ocular Disease

Berdy, Gregg J.; Leonardi, Andrea; Abelson, Mark B.

doi:10.1016/b978-1-4160-0016-7.50028-x

Cited by 1 publication

(2 citation statements)

References 139 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many topical ophthalmic medications have been approved by the US FDA and are available to treat SAC and PAC, each targeting different components of the allergic cascade [14]. There are selective H 1 -receptor antagonists, or antihistamines, such as levocabastine (Livostin ® ; Novartis, GA, USA) and emedastine (Emadine ® ; Alcon, TX, USA).…”

Section: Overview Of the Marketmentioning

confidence: 99%

“…SAC and PAC are characterized by an antigen-specific IgE mast cell-mediated response [14]. In a sensitized individual, the allergen binds to IgE-coated mast cells in the conjunctiva causing mast cell degranulation and the release of inflammatory mediators such as histamine, tryptase, prostaglandins, leukotrienes, neutrophil chemotactic factor, eosinophil chemotactic factor of anaphylaxis and platelet-activating factor (PAF) [10].…”

mentioning

confidence: 99%

See 1 more Smart Citation

Clinical safety and efficacy of bepotastine besilate ophthalmic solution to treat allergic conjunctivitis

Berdy

Oliff

2010

Expert Review of Ophthalmology

View full text Add to dashboard Cite

The mast cell-stabilizer-antihistamine class of medications has become physicians' first choice for treating seasonal allergic conjunctivitis owing to the rapid onset of action, long duration of effect and improved comfort. Bepotastine besilate ophthalmic solution 1.5% (Bepreve™, ISTA Pharmaceuticals, Inc., CA, USA) has recently been approved by the US FDA for the treatment of itching associated with the signs and symptoms of allergic conjunctivitis. Bepotastine besilate has multiple mechanisms of action, selectively inhibiting histamine H 1 receptors, stabilizing mast cells, inhibiting eosinophil infiltration, and inhibiting production of inflammatory cytokines or chemokines. Although not approved for other indications, a clinical study has shown that bepotastine besilate reduces nonocular (principally nasal) symptoms and thus may be particularly helpful for people with rhinoconjunctivitis. As per FDA approval, bepotastine besilate is well tolerated and safe for subjects as young as 2 years of age. Bepotastine besilate ophthalmic solution provides an alternative choice of treatment for allergic conjunctivitis. Keywords: allergic conjunctivitis • antihistamine • conjunctival allergen challenge • mast cell stabilizer • ocular allergy • rhinoconjunctivitis Clinical safety and efficacy of bepotastine besilate ophthalmic solution to treat allergic conjunctivitis Expert Rev. Ophthalmol. 5(5), 595-602 (2010) For reprint orders, please contact reprints@expert-reviews.com Expert Review of Ophthalmology Downloaded from informahealthcare.com by Nyu Medical Center on 07/30/15 For personal use only.

show abstract

Section: Overview Of the Marketmentioning

confidence: 99%

mentioning

confidence: 99%